Tanja Obradovic: Carisma Therapeutics just announced that first cancer patient with solid tumor received CAR-monocyte

Tanja Obradovic shared a post on LinkedIn:

”As of yesterday new cell therapy modality may be on the horizon consisting of first CAR-monocyte product.

Biotech Carisma Therapeutics just announced that first cancer patient with solid tumor received CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-monocyte) cellular therapy with over-expression of human epidermal growth factor receptor 2 (HER2).

Trial (NCT06254807) is conducted in patients with solid tumors with HER-2 positivity tested by IHC using standard assay resulting in 3+, or 2+ with confirmation by ISH testing with non-breast, non gastroesophageal tumors determined for positivity according to the breast cancer ASCO/CAP guidelines.

Completion is expected 1Q2025 when we can see if safety and initial efficacy of this novel approach delivers promise of improvement.”

Read further.
Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.